Chargement en cours...
Identifying optimal candidates of transarterial chemoembolization (TACE) vs. sorafenib in patients with unresectable hepatocellular carcinoma
BACKGROUND: Sorafenib has been recommended as the first-line treatment and shown to prolong median overall survival (OS) of patients with advanced unresectable hepatocellular carcinoma (HCC). Recently, a growing amount of research has supported the application of transarterial chemoembolization (TAC...
Enregistré dans:
| Publié dans: | Ann Transl Med |
|---|---|
| Auteurs principaux: | , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
AME Publishing Company
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7290559/ https://ncbi.nlm.nih.gov/pubmed/32566614 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2020.02.123 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|